✨ Free AI Report
KALA BIO, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research KALA BIO, Inc.
Company Research

KALA BIO, Inc.: Business Overview, Financials & Competitive Analysis

KALA BIO, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Turnaround play dependent on clinical trial success (KPI-012 CHASE trial) and AI platform monetization, with stock price suggesting significant distress but potential optionality in emerging psychedelic medicine and biotech AI infrastructure markets.

What is KALA BIO, Inc.'s industry? KALA BIO, Inc. (kalarx.com) operates in Pharmaceuticals. AskCyborg classifies KALA BIO, Inc. under Pharmaceuticals in its company registry.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare and severe eye diseases, particularly focusing on corneal and retinal disorders. The company recently pivoted to a dual-strate...

4/ 10Mixed

Cyborg Score thesis

Turnaround play dependent on clinical trial success (KPI-012 CHASE trial) and AI platform monetization, with stock price...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest KALA BIO, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for KALA BIO, Inc.

AskCyborg analysts argue the bull and bear cases for KALA BIO, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
KALA BIO, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

KALA BIO, Inc. Overview

Pro stress-test →

KALA BIO, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare and severe eye diseases, particularly focusing on corneal and retinal disorders. The company recently pivoted to a dual-strategy model combining its proprietary mesenchymal stem cell secretome (MSC-S) platform with an emerging AI infrastructure platform-as-a-service business.

Strategic Profile

Pro stress-test →

The company is positioned at the intersection of regenerative medicine and enterprise AI, leveraging its exclusive worldwide license for the Researgency AI research platform. With 38 employees and a highly specialized focus on rare ocular diseases and biotech AI infrastructure, KALA differentiates itself through its on-premises AI deployment model designed to protect proprietary client data.

Competitive Landscape

Pro stress-test →

KALA competes in two distinct markets: rare ophthalmology therapies (competitors include Aldeyra Therapeutics, Sarepta Therapeutics, ONL Therapeutics, Alnylam Pharmaceuticals) and biotech AI infrastructure (competing against enterprise AI providers entering biotech). KALA's on-premises deployment model for proprietary data security and focus on rare diseases represent differentiation, though larger pharmaceutical companies and well-funded AI firms pose competitive threats.

Industry Context

KALA BIO, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2009 · Headquarters: Arlington, Massachusetts · Employees: 38 · Market cap: $255M

What the analysts stress-tested

The top findings that survived the multi-agent debate for KALA BIO, Inc..

  • Recently rebranded from Kala Pharmaceuticals (Aug 2023) to reflect strategic expansion beyond traditional drug development into regenerative medicine and AI-driven biotech infrastructure
  • Lead candidate KPI-012 (MSC-S therapy) in Phase 2b CHASE trial for persistent corneal epithelial defects with FDA Orphan Drug and Fast Track designations, addressing ~100,000 US cases annually
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Announced celebration of Trump Executive Order prioritizing psychedelic medicine review and allocating $50M federal funding for research
  • March 2026Launched Bionic Intelligence Research Agent as commercial deployment of Researgency AI infrastructure platform
  • +1 moreTrack every material event for KALA BIO, Inc. as it happens. Explore monitoring →
Get alerted when KALA BIO, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Aldeyra TherapeuticsRare eye disease therapies development→Sarepta TherapeuticsGene therapy and rare disease focus→Alnylam PharmaceuticalsRNAi therapeutics for rare diseases→Red Light HollandPsychedelic therapy development client→

Compare KALA BIO, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

KALA BIO, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about KALA BIO, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare KALA BIO, Inc. and its top competitor on Cyborg Score”
“What did KALA BIO, Inc. do this quarter?”
“Is KALA BIO, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does KALA BIO, Inc. do?+
KALA BIO, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare and severe eye diseases, particularly focusing on corneal and retinal disorders. The company recently pivoted to a dual-strate...
What is KALA BIO, Inc.'s Cyborg Score?+
KALA BIO, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are KALA BIO, Inc.'s main competitors?+
Named competitors include Aldeyra Therapeutics, Sarepta Therapeutics, Alnylam Pharmaceuticals, Red Light Holland. The full competitive landscape is in the AskCyborg report.
How can I get the full KALA BIO, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the KALA BIO, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track KALA BIO, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.